Experimental Vaccine Shows Promise Against Pancreatic Cancer in Trial

A phase 1 clinical trial published July 16, 2026, in Cancer Discovery found an experimental vaccine safe for humans at high risk of developing pancreatic cancer.

Researchers at Johns Hopkins reported that 18 of 20 participants, or 90%, developed a median 18-fold increase in mutant KRAS-specific T-cell responses after receiving four doses over 13 weeks.

After a median follow-up of 16.5 months, none of the 20 participants developed cancer, with all reported side effects classified as mild to moderate.